Feldmüller, M., Jodl, S. J., Ploeger, B., Wagenfeld, A., Wiesinger, H., Zollmann, F. S., . . . Höchel, J. Zabedosertib, a novel interleukin-1 receptor-associated kinase-4 inhibitor, shows a favorable pharmacokinetic and safety profile across multiple phase 1 studies. Frontiers Media S.A.
Chicago Style (17th ed.) CitationFeldmüller, Maximilian, et al. Zabedosertib, a Novel Interleukin-1 Receptor-associated Kinase-4 Inhibitor, Shows a Favorable Pharmacokinetic and Safety Profile Across Multiple Phase 1 Studies. Frontiers Media S.A.
MLA (9th ed.) CitationFeldmüller, Maximilian, et al. Zabedosertib, a Novel Interleukin-1 Receptor-associated Kinase-4 Inhibitor, Shows a Favorable Pharmacokinetic and Safety Profile Across Multiple Phase 1 Studies. Frontiers Media S.A.
Warning: These citations may not always be 100% accurate.